14.88

2.62% 0.38

After Hours: 14.89 0.010 +0.07%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $14.88, with a volume of 1.13M. It is up +2.62% in the last 24 hours and up +12.81% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Previous Close:

$14.50

Open:

$14.5

24h Volume:

1.13M

Relative Volume:

0.76

Market Cap:

$2.11B

Revenue:

Net Income/Loss:

$-42.76M

P/E Ratio:

-46.38

EPS:

-0.3208

Net Cash Flow:

$-42.09M

1W Performance:

+3.48%

1M Performance:

+12.81%

6M Performance:

+22.98%

1Y Performance:

+125.45%

1-Day Range:

$14.30

$14.95

1-Week Range:

$13.36

$15.35

52-Week Range:

$5.3801

$16.12

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (619)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2026-05-05

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	14.88	2.06B	0	-42.76M	-42.09M	-0.3208
VRTX Vertex Pharmaceuticals Inc	435.17	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	712.77	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	813.28	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	284.84	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	310.75	32.38B	5.36B	287.73M	924.18M	2.5229

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

07:10 AM

Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView

07:10 AM

May 10, 2026

Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

May 10, 2026

F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat

May 10, 2026

Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat

May 10, 2026

May 09, 2026

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - MarketBeat

May 09, 2026

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat

May 09, 2026

May 08, 2026

Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat

May 08, 2026